{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:42:07Z","timestamp":1793234527095,"version":"4.5.0"},"reference-count":148,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum toxin A (Botox) had been considered a promising drug that has an effect on functional disorders of the lower urinary tract. Because Botox exhibits anti-inflammatory and antispasmodic effects, Botox injection into the bladder can decrease detrusor contractility, reduce bladder hypersensitivity, and eliminate painful sensations. Injecting Botox into the bladder outlet can relax the hyperactivity of the bladder neck, and of the urethral smooth and striated muscles. Based on these therapeutic effects, Botox has been widely applied to treat lower-urinary-tract dysfunctions (LUTDs) such as overactive bladder and neurogenic detrusor overactivity. However, this treatment has not been licensed for use in other LUTDs such as interstitial cystitis, voiding dysfunction due to benign prostatic hyperplasia in men, and dysfunctional voiding in women. Botox has also not been approved for the treatment of children with overactive bladder and dysfunctional voiding; in patients with spinal cord injuries with detrusor sphincter dyssynergia and autonomic dysreflexia; or for poorly relaxed external sphincter in non-neurogenic patients. This article reviews the current knowledge regarding Botox treatment for LUTDs and discusses the potential clinical applications of Botox, as well as work that can be conducted in the future.<\/jats:p>","DOI":"10.3390\/toxins14070498","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:19:21Z","timestamp":1658189961000},"page":"498","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4771","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"first","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Jhang, J.F., and Kuo, H.C. (2016). Botulinum toxin A and lower urinary tract dysfunction: Pathophysiology and mechanisms of action. Toxins, 8.","DOI":"10.3390\/toxins8040120"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ncpuro0839","article-title":"Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: Where we are now and where we are going","volume":"4","author":"Sahai","year":"2007","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2011.11.001","article-title":"Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain","volume":"12","author":"Dolly","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","article-title":"An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders","volume":"65","author":"Mangera","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ncpuro1124","article-title":"Drug insight: Biological effects of botulinum toxin A in the lower urinary tract","volume":"5","author":"Chancellor","year":"2008","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.urology.2005.02.002","article-title":"Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics","volume":"66","author":"Kuo","year":"2005","journal-title":"Urology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/nau.21054","article-title":"Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics","volume":"30","author":"Kuo","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/nau.21150","article-title":"Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: Lack of anticholinergic efficacy versus intolerability","volume":"30","author":"Makovey","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/ijcp.12443","article-title":"OnabotulinumtoxinA 100 U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder","volume":"68","author":"Sievert","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","article-title":"Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus report","volume":"55","author":"Apostolidis","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/iju.12205","article-title":"Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity","volume":"21","author":"Veeratterapillay","year":"2014","journal-title":"Int. J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/nau.24845","article-title":"Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women","volume":"41","author":"Hendrickson","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/luts.12384","article-title":"Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. Low","volume":"13","author":"Wang","year":"2021","journal-title":"Urin. Tract Symptoms"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.purol.2020.07.242","article-title":"Long-term follow-up reveals a low persistence rate of abobotulinumtoxinA injections for idiopathic overactive bladder","volume":"30","author":"Baron","year":"2020","journal-title":"Prog. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/nau.24820","article-title":"Evaluation of the effect of 100 U of Onabotulinum toxin A on detrusor contractility in women with idiopathic OAB: A multicentre prospective study","volume":"41","author":"Minafra","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00192-021-05030-3","article-title":"Treatment of refractory overactive bladder with onabotulinumtoxinA vs. PTNS: TROOP trial","volume":"33","author":"Kopcsay","year":"2022","journal-title":"Int. Urogynecol. J."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lo, C.W., Wu, M.Y., Yang, S.S., Jaw, F.S., and Chang, S.J. (2020). Comparing the efficacy of onabotulinumtoxinA, sacral neuromodulation, and peripheral tibial nerve stimulation as third line treatment for the management of overactive bladder symptoms in adults: Systematic review and network meta-analysis. Toxins, 12.","DOI":"10.3390\/toxins12020128"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00192-020-04392-4","article-title":"Sacral neuromodulation for overactive bladder in women: Do age and comorbidities make a difference?","volume":"32","author":"High","year":"2021","journal-title":"Int. Urogynecol. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/JU.0000000000000656","article-title":"Cost-effectiveness of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: Results of the ROSETTA randomized trial","volume":"203","author":"Harvie","year":"2020","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/nau.24670","article-title":"Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed botulinum toxin herapy: Results in a large cohort of patients","volume":"40","author":"Reekmans","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.eururo.2018.02.011","article-title":"Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: A randomized trial","volume":"74","author":"Amundsen","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","article-title":"Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: A single-center study","volume":"65","author":"Kuo","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.juro.2014.07.008","article-title":"Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: A prospective, multicenter, double-blind, randomized trial","volume":"192","author":"Chuang","year":"2014","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liu, H.T., Chen, S.H., Chancellor, M.B., and Kuo, H.C. (2015). Presence of cleaved synaptosomal-associated protein-25 and decrease of purinergic receptors P2X3 in the bladder urothelium influence efficacy of botulinum toxin treatment for overactive bladder syndrome. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134803"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.juro.2017.02.021","article-title":"A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxinA for interstitial cystitis\/bladder pain syndrome","volume":"198","author":"Chuang","year":"2017","journal-title":"J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Jiang, Y.H., Yu, W.R., and Kuo, H.C. (2020). Therapeutic effect of botulinum toxin A on sensory bladder disorders-fom bench to bedside. Toxins, 12.","DOI":"10.3390\/toxins12030166"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chen, P.Y., Cheng, J.H., Wu, Z.S., and Chuang, Y.C. (2022). New frontiers of extracorporeal shock wave medicine in urology from bench to clinical studies. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030675"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Jiang, Y.H., Jhang, J.F., Lee, Y.K., and Kuo, H.C. (2022). Low-energy shock wave plus intravesical instillation of botulinum toxin A for interstitial cystitis\/bladder pain syndrome: Pathophysiology and preliminary result of a novel minimally invasive treatment. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020396"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/nau.24879","article-title":"Botulinum toxin for treating overactive bladder in men: A systematic review","volume":"41","author":"Truzzi","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/nau.24871","article-title":"Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: Multi-institutional collaboration from the SUFU research network","volume":"41","author":"Reynolds","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2012.11.089","article-title":"Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity","volume":"189","author":"Liao","year":"2013","journal-title":"J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/nau.24809","article-title":"The use of onabotulinumtoxinA to treat idiopathic overactive bladder in elderly patients is in need of study","volume":"41","author":"Manns","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: Risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.euf.2020.06.013","article-title":"Predictors of poor response and adverse events following botulinum toxin A for refractory idiopathic overactive bladder: A systematic review","volume":"7","author":"Abrar","year":"2021","journal-title":"Eur. Urol. Focus"},{"key":"ref_39","first-page":"235","article-title":"Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: A systematic review and meta-analysis","volume":"33","author":"Shawer","year":"2022","journal-title":"Int. Urogynecol. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients","volume":"139","author":"Dykstra","year":"1988","journal-title":"J. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eururo.2005.12.012","article-title":"Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes","volume":"49","author":"Kalsi","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1468-1331.2011.03618.x","article-title":"Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity","volume":"19","author":"Conte","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2007.08.039","article-title":"Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections","volume":"53","author":"Bentaleb","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1464-410X.2009.08368.x","article-title":"Patients\u2019 perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury","volume":"104","author":"Hori","year":"2009","journal-title":"Br. J. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: A randomized, double-blind trial","volume":"185","author":"Herschorn","year":"2011","journal-title":"J. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wang, C.C., Chou, E.C., Chuang, Y.C., Lin, C.C., Hsu, Y.C., Liao, C.H., and Kuo, H.C. (2021). Effectiveness and safety of intradetrusor onabotulinumtoxinA injection for neurogenic detrusor overactivity and overactive bladder patients in Taiwan\u2014A phase IV prospective, iterventional, Mmultiple-center study (rstore Sstudy). Toxins, 13.","DOI":"10.3390\/toxins13120911"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Cheng, T., Shuang, W.B., Jia, D.D., Zhang, M., Tong, X.N., Yang, W.D., Jia, X.M., and Li, S. (2016). Efficacy and safety of onabotulinumtoxinA in ptients with Nnurogenic detrusor overactivity: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159307"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00345-020-03211-1","article-title":"Are 200 units of onabotulinumtoxin A sufficient for the suppression of neurogenic detrusor overactivity in individuals with established 300-unit botulinum toxin treatment? A retrospective cohort study","volume":"39","author":"Krebs","year":"2021","journal-title":"World J. Urol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2021.09.045","article-title":"Prospective Evaluation of intradetrusor injections of onabotulinumtoxinA in adults with spinal dysraphism","volume":"161","author":"Mackay","year":"2022","journal-title":"Urology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/iju.14602","article-title":"Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension","volume":"28","author":"Honda","year":"2021","journal-title":"Int. J. Urol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41393-019-0411-0","article-title":"Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury","volume":"58","author":"Hebert","year":"2020","journal-title":"Spinal Cord"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/nau.23354","article-title":"Is repeat botulinum toxin A injection valuable for neurogenic detrusor overactivity\u2014A systematic review and meta-analysis","volume":"37","author":"Ni","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/nau.24490","article-title":"Intradetrusor botulinum toxin injections (300 units) for the treatment of poorly compliant bladders in patients with adult neurogenic lower urinary tract dysfunction","volume":"39","author":"Johnson","year":"2020","journal-title":"Neurourol. Urodyn."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lee, C.L., Jhang, J.F., Jiang, Y.H., and Kuo, H.C. (2022). Real-world data regarding satisfaction to botulinum toxin A injection into the urethral sphincter and further bladder management for voiding dysfunction among patients with spinal cord injury and voiding dysfunction. Toxins, 14.","DOI":"10.3390\/toxins14010030"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lin, C.C., and Kuo, H.C. (2022). Video-urodynamic characteristics and predictors of switching from botulinum neurotoxin A injection to augmentation enterocystoplasty in spinal cord injury patients. Toxins, 14.","DOI":"10.3390\/toxins14010047"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urology.2019.03.010","article-title":"Botulinum toxin type A injection after failure of augmentation enterocystoplasty performed for neurogenic detrusor overactivity: Preliminary results of a salvage strategy. The ENTEROTOX Study","volume":"129","author":"Michel","year":"2019","journal-title":"Urology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.juro.2018.10.012","article-title":"Long-term discontinuation of botulinum toxin A intradetrusor injections for neurogenic detrusor overactivity: A multicenter study","volume":"201","author":"Baron","year":"2019","journal-title":"J. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chen, S.F., Jiang, Y.H., Jhang, J.F., and Kuo, H.C. (2022). Satisfaction with detrusor onabotulinumtoxinA injections and cnversion to other badder management in patients with chronic spinal cord injury. Toxins, 14.","DOI":"10.3390\/toxins14010035"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0025-7125(03)00151-2","article-title":"Interstitial cystitis: A chronic pelvic pain syndrome","volume":"88","author":"Nickle","year":"2004","journal-title":"Med. Clin. N. Am."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.juro.2009.02.122","article-title":"Clinical phenotyping of women with interstitial cystitis\/painful bladder syndrome: A key to classification and potentially improved management","volume":"182","author":"Nickel","year":"2009","journal-title":"J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.eururo.2012.05.023","article-title":"Mapping of pain phenotypes in female patients with bladder pain syndrome\/interstitial cystitis and controls","volume":"62","author":"Tripp","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/01.ju.0000118938.09119.a5","article-title":"Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis","volume":"171","author":"Slobodov","year":"2004","journal-title":"J. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/00365590701871518","article-title":"Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome\/interstitial cystitis, bladder capacity and potassium sensitivity","volume":"42","author":"Daha","year":"2008","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0090-4295(96)00322-6","article-title":"A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis","volume":"48","author":"Hurst","year":"1996","journal-title":"Urology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s11255-016-1295-y","article-title":"Efficacy and safety of botulinum toxin injection for interstitial cystitis\/bladder pain syndrome: A systematic review and meta-analysis","volume":"48","author":"Shim","year":"2016","journal-title":"Int. Urol. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.urology.2004.06.073","article-title":"Botulinum toxin A has antinociceptive effects in treating interstitial cystitis","volume":"64","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.juro.2007.10.032","article-title":"Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup","volume":"179","author":"Giannantoni","year":"2008","journal-title":"J. Urol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2174\/156720110793566317","article-title":"Botulinum A toxin intravesical injections for painful bladder syndrome: Impact upon pain, psychological functioning and quality of Life","volume":"7","author":"Giannantoni","year":"2010","journal-title":"Curr. Drug. Deliv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","article-title":"Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome","volume":"104","author":"Kuo","year":"2009","journal-title":"BJU. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1464-410X.2012.11466.x","article-title":"Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis\/bladder pain syndrome","volume":"111","author":"Shie","year":"2013","journal-title":"BJU. Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/nau.22760","article-title":"Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment\u2014A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial","volume":"35","author":"Kuo","year":"2016","journal-title":"Neurourol. Urodyn."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Chen, C.L., and Meng, E. (2020). Can botulinum toxin A play a role In treatment of chronic pelvic pain syndrome in fmale patients?\u2014Clinical and animal evidence. Toxins, 12.","DOI":"10.3390\/toxins12020110"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/luts.12334","article-title":"Botulinum toxin A injection in the treatment of chronic pelvic pain with hypertonic pelvic floor in women: Treatment techniques and results","volume":"13","author":"Chuang","year":"2021","journal-title":"Low. Urin. Tract Symptoms"},{"key":"ref_77","first-page":"109","article-title":"Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis","volume":"16","author":"Lee","year":"2013","journal-title":"Pain Physician"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.3390\/toxins7104283","article-title":"Long-term efficacy and safety of repeated intravescial onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis\/badder pain syndrome","volume":"7","author":"Lee","year":"2015","journal-title":"Toxins"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/nau.23475","article-title":"Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment\u2014A prospective, randomized, clinical trial","volume":"37","author":"Jiang","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wang, H.J., Yu, W.R., Ong, H.L., and Kuo, H.C. (2019). Predictive factors for a satisfactory treatment outcome with intravesical botulinum toxin A injection in patients with interstitial cystitis\/badder pain syndrome. Toxins, 11.","DOI":"10.3390\/toxins11110676"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00192-021-04878-9","article-title":"Trigone as a diagnostic and therapeutic target for bladder-centric interstitial cystitis\/bladder pain syndrome","volume":"32","author":"Dobberfuhl","year":"2021","journal-title":"Int. Urogynecol. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2010.02.031","article-title":"Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome\/interstitial cystitis","volume":"58","author":"Pinto","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_83","first-page":"10125","article-title":"Injection location does not impact botulinum toxin A efficacy in interstitial cystitis\/bladder pain syndrome patients","volume":"27","author":"Evans","year":"2020","journal-title":"Can. J. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11255-022-03107-6","article-title":"An indirect comparison meta-analysis of noninvasive intravesical instillation and intravesical injection of botulinum toxin-A in bladder disorders","volume":"54","author":"Yunfeng","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Jhang, J.F., and Kuo, H.C. (2018). Novel applications of onabotulinumtoxinA in lower urinary tract dysfunction. Toxins, 10.","DOI":"10.3390\/toxins10070260"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0090-4295(01)01641-7","article-title":"Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: Preliminary results","volume":"59","author":"Michael","year":"2002","journal-title":"Urology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.ju.0000108892.35041.2d","article-title":"Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia","volume":"171","author":"Riccabona","year":"2004","journal-title":"J. Urol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.urology.2006.05.056","article-title":"Intravesical injection of botulinum toxin type A: Management of neuropathic bladder and bowel dysfunction in children with myelomeningocele","volume":"68","author":"Kajbafzadeh","year":"2006","journal-title":"Urology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.urology.2009.09.087","article-title":"Intravesical injections of botulinum toxin type A for management of neuropathic bladder: A comparison of two methods","volume":"76","author":"Safari","year":"2010","journal-title":"Urology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0029-1246193","article-title":"Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children","volume":"20","author":"Marte","year":"2010","journal-title":"Eur. J. Pediatr. Surg."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/00365599.2011.590997","article-title":"Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: A pilot study","volume":"45","author":"Anttila","year":"2011","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00383-011-3039-5","article-title":"Urinary incontinence in children: Botulinum toxin is a safe and effective treatment option","volume":"28","author":"McDowell","year":"2012","journal-title":"Pediatr. Surg. Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jpurol.2009.01.005","article-title":"Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity\/neurogenic overactive bladder: A systematic literature review","volume":"5","author":"Mouracade","year":"2009","journal-title":"J. Pediatr. Urol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/nau.24588","article-title":"OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children","volume":"40","author":"Austin","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/nau.24778","article-title":"Onabotulinumtoxin A (Botox): A reasonable alternative for refractory neurogenic bladder dysfunction in children and young adults","volume":"40","author":"Softness","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"351.e1","DOI":"10.1016\/j.jpurol.2022.02.007","article-title":"Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder","volume":"18","author":"Lambregts","year":"2022","journal-title":"J. Pediatr. Urol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"801517","DOI":"10.3389\/fped.2021.801517","article-title":"Mirabegron in overactive bladder and its role in exit strategy after botulinum toxin treatment in children","volume":"9","author":"Tan","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"94.e1","DOI":"10.1016\/j.jpurol.2015.06.019","article-title":"Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children","volume":"12","author":"Greer","year":"2016","journal-title":"J. Pediatr. Urol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.urology.2017.09.005","article-title":"Clinical and urodynamic results of repeated intradetrusor onabotulinum toxin A injections in refractory neurogenic dtrusor overactivity: Up to 5 injections in a cohort of children with myelodysplasia","volume":"111","author":"Sekerci","year":"2018","journal-title":"Urology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/nau.23352","article-title":"Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity","volume":"37","author":"Joussain","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.purol.2021.10.010","article-title":"Repeated detrusor injection of botulinum toxin A for neurogenic bladder in children: A long term option?","volume":"32","author":"Madec","year":"2022","journal-title":"Prog. Urol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000089739","article-title":"Investigation of dysfunctional voiding in children with urgency frequency syndrome and urinary incontinence","volume":"76","author":"Kuo","year":"2006","journal-title":"Urol. Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.juro.2006.03.119","article-title":"Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder","volume":"176","author":"Mokhless","year":"2006","journal-title":"J. Urol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.juro.2013.10.034","article-title":"Long-term efficacy and durability of botulinum-A toxin for refractory dysfunctional voiding in children","volume":"191","author":"Vricella","year":"2014","journal-title":"J. Urol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.juro.2007.03.185","article-title":"The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children","volume":"178","author":"Franco","year":"2007","journal-title":"J. Urol."},{"key":"ref_106","first-page":"24","article-title":"Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study","volume":"71","author":"Dykstra","year":"1990","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/01.ju.0000091281.50081.f0","article-title":"Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction","volume":"170","author":"Kuo","year":"2003","journal-title":"J. Urol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1097\/01.ju.0000127725.48479.89","article-title":"Emerging role of botulinum toxin in the treatment of voiding dysfunction","volume":"171","author":"Smith","year":"2004","journal-title":"J. Urol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0302-2838(02)00209-9","article-title":"Botulinum a toxin and detrusor sphincter dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease","volume":"42","author":"Petit","year":"2002","journal-title":"Eur. Urol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.apmr.2011.11.020","article-title":"Spinal Cord Injury Rehabilitation Evidence Research Team. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury","volume":"93","author":"Mehta","year":"2012","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.urology.2004.08.016","article-title":"Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra","volume":"65","author":"Smith","year":"2005","journal-title":"Urology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000079697","article-title":"Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions","volume":"73","author":"Chen","year":"2004","journal-title":"Urol. Int."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"jrm00264","DOI":"10.2340\/jrm.v54.122","article-title":"Concomitant detrusor and external urethral sphincter botulinum toxin-A injections in male spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia","volume":"54","author":"Huang","year":"2022","journal-title":"J. Rehabil. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urology.2020.03.007","article-title":"Use of botulinum toxin A (BoNT-A) in detrusor external sphincter dyssynergia (DESD): A systematic review and meta-analysis","volume":"140","author":"Goel","year":"2020","journal-title":"Urology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol. Urodyn. Off. J. Int. Cont. Soc."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)55287-8","article-title":"The female urethral syndrome: External sphincter spasm as etiology","volume":"124","author":"Kaplan","year":"1980","journal-title":"J. Urol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0022-5347(17)45077-4","article-title":"Nonneurogenic neurogenic bladder (the Hinmann syndrome)\u201415 years later","volume":"136","author":"Hinman","year":"1986","journal-title":"J. Urol."},{"key":"ref_118","first-page":"217","article-title":"Dysfunctional voiding in women with lower urinary tract symptoms","volume":"12","author":"Kuo","year":"2000","journal-title":"Tzu. Chi. Med. J."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Jiang, Y.H., Lee, C.L., Chen, S.F., and Kuo, H.C. (2021). Therapeutic effects of urethral sphincter botulinum toxin A injection on dysfunctional voiding with different videourodynamic characteristics in non-neurogenic women. Toxins, 13.","DOI":"10.3390\/toxins13050362"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Ou, Y.-C., Huang, K.-H., Jan, H.-C., Kuo, H.-C., Kao, Y.-L., and Tsai, K.-J. (2021). Therapeutic efficacy of urethral sphincteric botulinum toxin injections for female sphincter dysfunctions and a search for predictive factors. Toxins, 13.","DOI":"10.3390\/toxins13060398"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Lee, Y.K., and Kuo, H.C. (2019). Therapeutic effects of botulinum toxin A, via urethral sphincter injection on voiding dysfunction due to different bladder and urethral sphincter dysfunctions. Toxins, 11.","DOI":"10.3390\/toxins11090487"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.urology.2004.10.077","article-title":"Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates","volume":"65","author":"Kuo","year":"2005","journal-title":"Urology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1464-410X.2006.06479.x","article-title":"Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia","volume":"98","author":"Chuang","year":"2006","journal-title":"BJU. Int."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00345-012-0851-z","article-title":"Transurethral intraprostatic Botulinum toxin-A injection: A novel treatment for BPH refractory to current medical therapy in poor surgical candidates","volume":"31","author":"Enshaei","year":"2013","journal-title":"World J. Urol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/2090598X.2019.1662214","article-title":"Transperineal intraprostatic injection of botulinum neurotoxin A vs. transurethral resection of prostate for management of lower urinary tract symptoms secondary to benign prostate hyperplasia: A prospective randomised study","volume":"17","author":"Gharib","year":"2019","journal-title":"Arab. J. Urol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/nau.23390","article-title":"Intraprostatic botulinum toxin type \u201cA\u201d injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation","volume":"37","author":"Totaro","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/pros.23805","article-title":"Outcome of botulinum toxin-A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study","volume":"79","author":"Moussa","year":"2019","journal-title":"Prostate"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","article-title":"A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia","volume":"63","author":"Marberger","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11255-015-1153-3","article-title":"Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: A systematic review and meta-analysis","volume":"48","author":"Shim","year":"2016","journal-title":"Int. Urol. Nephrol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0929-6646(10)60008-3","article-title":"Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction","volume":"108","author":"Chen","year":"2009","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.urology.2005.04.029","article-title":"Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates","volume":"66","author":"Chuang","year":"2005","journal-title":"Urology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"E837-44","DOI":"10.1111\/j.1464-410X.2012.11288.x","article-title":"Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study","volume":"110","author":"Sacco","year":"2012","journal-title":"BJU. Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/00365590902811537","article-title":"Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy","volume":"43","author":"Kuo","year":"2009","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/nau.23714","article-title":"Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity","volume":"37","author":"Jiang","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_135","first-page":"1179562X18811340","article-title":"A prospective study to evaluate the efficacy of botulinum toxin-A in the management of dysfunctional voiding in women","volume":"11","author":"Krishnappa","year":"2018","journal-title":"Clin. Med. Insights Womens Health"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"463574","DOI":"10.1100\/2012\/463574","article-title":"Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: Randomized study comparing two doses","volume":"2012","author":"Arnouk","year":"2012","journal-title":"Sci. World J."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Wu, S.Y., Jiang, Y.H., Jhang, J.F., Hsu, Y.H., Ho, H.C., and Kuo, H.C. (2022). Inflammation and barrier function deficits in the bladder urothelium of ptients with chronic spinal cord injury and recurrent urinary tract infections. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020220"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/bju.12896","article-title":"\u03b3Epithelial Na(+) Channel (\u03b3ENaC) and the Acid-Sensing Ion Channel 1 (ASIC1) expression in the urothelium of patients with neurogenic detrusor overactivity","volume":"116","author":"Traini","year":"2015","journal-title":"BJU. Int."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/tcmj.tcmj_38_20","article-title":"Recurrent urinary tract infection in women and overactive bladder\u2014Is there a relationship?","volume":"33","author":"Ke","year":"2020","journal-title":"Tzu. Chi. Med. J."},{"key":"ref_140","first-page":"659","article-title":"In patients with neurogenic detrusor overactivity and Hinman\u2019s syndrome: Would intravesical botox injections decrease the incidence of symptomatic urinary tract infections","volume":"13","author":"Banakhar","year":"2021","journal-title":"Res. Rep. Urol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/SPV.0000000000000753","article-title":"Does a recent urinary tract infection increase the risk of postprocedure urinary tract infection after onabotulinum toxin A?","volume":"27","author":"Bickhaus","year":"2021","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00192-019-04007-7","article-title":"Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation","volume":"31","author":"Streit","year":"2020","journal-title":"Int. Urogynecol. J."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/PHM.0000000000001413","article-title":"Outcome of different approaches to reduce urinary tract infection in patients with spinal cord lesions: A systematic review","volume":"99","author":"Chang","year":"2020","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/j.1464-410X.2010.09435.x","article-title":"Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment","volume":"106","author":"Mouttalib","year":"2010","journal-title":"BJU. Int."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Chen, G., Liao, L., and Zhang, F. (2019). Efficacy and safety of botulinum toxin a injection into urethral sphincter for underactive bladder. BMC Urol., 19.","DOI":"10.1186\/s12894-019-0490-4"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s11255-022-03175-8","article-title":"Treatment outcomes of detrusor underactivity in women based on clinical and videourodynamic characteristics","volume":"54","author":"Chen","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/luts.12195","article-title":"Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity","volume":"11","author":"Jiang","year":"2019","journal-title":"Low. Urin. Tract Symptoms"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Kuo, H.C. (2020). Botulinum toxin paves the way for the treatment of functional lower urinary tract dysfunction. Toxins, 12.","DOI":"10.3390\/toxins12060394"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/7\/498\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:52:47Z","timestamp":1760140367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/7\/498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":148,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["toxins14070498"],"URL":"https:\/\/doi.org\/10.3390\/toxins14070498","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]}}}